GUTS Stock Reels As Class Actions Follow 75% Collapse

Fractyl Health, Inc. stocks have been trading down by -48.78 percent amid heightened concern over its early-stage metabolic therapies.

Live Update At 08:33:05 EDT: On Friday, October 16, 2026 Fractyl Health, Inc. stock [NASDAQ: GUTS] is trending down by -48.78%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GUTS is trading like a classic fallen biotech story. The daily chart shows a stunning move: the stock closed near $0.41 on 2026/10/02, then printed in the $4s from 2026/10/05 onward. That type of 10x reset usually reflects a reverse split or similar corporate action layered on top of massive volatility.

Over the last several sessions, GUTS has chopped between roughly $4.00 and $4.80, with repeated intraday pushes toward $4.70–$4.80 getting sold. That tells traders there is overhead supply, likely from bagholders looking to exit on any bounce. The 5‑minute tape reinforces the chaos: premarket swings from about $4.80 down into the low $2s in less than an hour, then more whipsaws, show GUTS acting like a day-trader playground rather than a stable biotech.

More Breaking News

• OPK Stock Holds Key Support As Traders Study Downtrend
• DNN Stock Holds Support As Uranium Traders Watch Next Move
• VBIO Regains Nasdaq Compliance As $100M Shelf Sets Trading Stage
• Opendoor Stock Holds Key Support As Wall Street Resets Expectations

Fundamentally, Fractyl Health is deep in the red. For the quarter ending 2026/06/30, GUTS posted a net loss of about $25.5M and negative operating cash flow of roughly $15.9M. Cash sits near $51.4M, with working capital around $33.9M, so the balance sheet gives it time, but not forever. Returns on assets are sharply negative and book value per share is below zero, underlining that GUTS is a high-risk, story-driven trade, not a value play.

Why Traders Are Watching GUTS Now

Traders are glued to GUTS because few setups combine clinical drama, legal risk, and chart volatility like this one. The core story centers on Revita, Fractyl Health’s procedure aimed at weight maintenance after GLP‑1 therapy and metabolic disease. Multiple class actions claim the company overstated Revita’s efficacy and commercial prospects, especially around the REMAIN‑1 Midpoint Cohort.

According to the complaints, management highlighted strong three‑month weight‑loss data while downplaying or not disclosing operational problems at an “outlier” clinical site. At the same time, GUTS allegedly relied on that upbeat interim picture to run two equity offerings in 2025/08 and 2025/09, pulling in about $76.7M. For traders, that combination — aggressive capital raises plus later data disappointment — is exactly what destroys trust.

The real breaking point came in 2026/01. More complete six‑month REMAIN‑1 data reportedly showed weaker‑than‑touted weight maintenance and meaningful weight regain, while site‑level issues were finally aired. GUTS then cratered roughly 68–75% in two trading days. Morgan Stanley followed with a downgrade and reduced peak sales estimates for Revita, essentially signaling that the Street was re‑rating the entire GUTS story.

Now, notices from firms like Pomerantz and others stress that traders who bought between 2025/01/13 and 2026/01/29 are being recruited for class actions, with one key lead‑plaintiff deadline on 2026/10/20. That legal overhang matters: as long as GUTS is fighting questions about data integrity and disclosure, many funds will stay on the sidelines. For active traders, that often means spikes are driven more by short covering, headlines, and technical squeezes than by fundamentals.

Conclusion

For active traders, GUTS is a textbook example of why you respect risk in speculative biotech names. Fractyl Health is now juggling steep quarterly losses, a bruised balance sheet, and a wave of securities class actions accusing it of overstating Revita’s prospects and hiding problems in the REMAIN‑1 trial. The roughly 75% collapse around the 2026/01 data release, followed by analyst downgrades, shows how fast narrative premium can vanish once trust breaks.

At the same time, the recent price action — post‑split style reset from under $1 into the $4s, violent premarket swings between $2 and $4‑plus — tells you GUTS remains a momentum magnet. That is attractive to day traders hunting range and liquidity, but dangerous for anyone who ignores tight risk controls. The legal timeline, with at least one 2026/10/20 lead‑plaintiff deadline, suggests the overhang will not clear quickly. This is exactly where emotional discipline matters: passing on a sketchy setup is often the right move. As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.”

In the words often repeated in the Tim Sykes community, “Volatility is opportunity for prepared traders, but a death trap for gamblers.” For GUTS, that means treating every trade as a quick, rule‑driven speculation — not a long‑term bet on how the lawsuit or Revita’s ultimate fate plays out. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.